Journal article
Pharmacological inhibition of STING reduces neuroinflammation-mediated damage post-traumatic brain injury
AL Fryer, A Abdullah, F Mobilio, A Jobling, Z Moore, M de Veer, G Zheng, BX Wong, JM Taylor, PJ Crack
British Journal of Pharmacology | WILEY | Published : 2024
DOI: 10.1111/bph.16347
Abstract
Background and Purpose: Traumatic brain injury (TBI) remains a major public health concern worldwide with unmet effective treatment. Stimulator of interferon genes (STING) and its downstream type-I interferon (IFN) signalling are now appreciated to be involved in TBI pathogenesis. Compelling evidence have shown that STING and type-I IFNs are key in mediating the detrimental neuroinflammatory response after TBI. Therefore, pharmacological inhibition of STING presents a viable therapeutic opportunity in combating the detrimental neuroinflammatory response after TBI. Experimental Approach: This study investigated the neuroprotective effects of the small-molecule STING inhibitor n-(4-iodophenyl)..
View full abstractGrants
Awarded by Brain Foundation
Funding Acknowledgements
This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC; Project Grant 1156744) to P.J.C and the Brain Foundation to A.A. We would like to thank the staff of the Melbourne Bioresources Platform for their expertise. Open access publishing facilitated by The University of Melbourne, as part of the Wiley - The University of Melbourne agreement via the Council of Australian University Librarians.